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Granuloma annulare (GA) is a benign inflammatory granuloma-
tous skin.1 Photodynamic therapy (PDT) has been described as
another therapeutic option for localized GA, with a degree of
recommendation B.2 Therefore, we have carried out a review of
all patients with GA treated with PDT in our Dermatology Unit.
We performed a retrospective observational study in San
Jorge Hospital (Huesca, Spain) including all patients diagnosed
with GA and treated with PDT between 2007 and 2018. Diagno-
sis of GA was clinical and a skin biopsy was performed if it was
necessary. In all patients, methyl aminolevulinate (MAL) or
aminolevulinic acid (ALA) was applied under occlusive and opa-
que dressing for 3 h and illuminated with LED 635 nm
(Aktilite, Uppsala, Sweden) with a fluence of 37 J/cm2. The
lesions were prepared by a soft curettage or microneedling, and
some lesions did not receive any kind of prior skin preparation.
Continuous variables were described using means and standard
deviations. Statistical analyses were carried out using SPSS soft-
ware (version 20.0; IBM Corp, Armonk, NY, USA).
Thirteen patients were included in the study (Table 1). Eleven
cases (84.6%) were women and two men (15.4%), with a mean
of 53 years old. Eighty-four per cent patients (n = 11) under-
went a previous biopsy to confirm the diagnosis of GA. The
majority received a pretreatment with curettage (38.5%, n = 5)
or microneedling (46.2%, n = 6). Seven patients (53.8%)
responded completely to PDT and four partially improved
(30.8%) (Fig. 1). Of the total of responding patients and those
who improved, 9 (81.81%) were treated with MAL, 1 (9.09%)
with ALA and 1 (9.09%) with both.. With regard to the number
of sessions, the majority received between one and three sessions
separated by four weeks with MAL. Seventy per cent (n = 9) tol-
erated the PDT session quite well, and 30% (n = 4) reported
moderate pain. Cosmetic result was excellent in all patients with
clinical remission, with just a slight hyperpigmentation in two
patients who have complete response.
To our knowledge, there are few articles analysing the effec-
tiveness of PDT for GA. The majority are isolated clinical cases3,4
or series of clinical cases,5,6 and they are summarized in table 1.
The largest one was published by Calzavara-Pinton et al.7 in a
retrospective analysis of real-life practice of off-label PDT using
MAL.
Compared PDT effectiveness with other treatments, for exam-
ple intralesional corticosteroids, this obtained complete clear-
ance of 70% of the patients compared with the 44% of placebo.2
Concerning cryosurgery, the response rate was 80% with a single
freeze-thaw cycle in a clinical trial including 31 patients but cos-
metic results with cryosurgery were good only in 11 patients
(39.3%) and crioatrophy occurred in four patients (21.1%).8
The cellular photodamage after PDT involves different death
pathways. The result of MAL-PDT depends on the thickness of
corner layer and epidermis, in inflammatory cutaneous diseases
with mononuclear and lymphocytic infiltration.7 ALA-PDT has
been demonstrated to induce in vivo apoptosis in lesional T-
lymphocytes in psoriatic plaques.9 The etiopathogenesis of GA is
still unknown, but some authors propose that T-helper cells have
an interaction with histiocytes and this leads to granuloma for-
mation. In addition, these T cells express interferon gamma and
the aggressive macrophages express tumour necrosis factor
(TNF-a) and matrix metalloproteinases that contribute to
inflammation and destruction.1 Therefore, to try to obtain a
good response and that apoptosis occurs in T-lymphocytes, it is
important to pretreat the skin lesion that favours the penetration
of the photosensitizer.
In conclusion, the efficacy of PDT in localized GA is similar
to other more established treatments and without adverse
effects. Until a clinical trial shows its real efficacy, PDT could be
considered after failure of other easier and cheaper treatments
such as topical or intralesional corticosteroids and maybe before
cryotherapy in order to avoid permanent scars.
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Figure 1 (a) Granuloma annulare (GA) in lower limbs. (b) Fluorescence before photodynamic therapy (PDT) session. (c) Hyperpigmenta-
tion 1 month later after two sessions of PDT separated by 4 weeks. (d) Complete resolution of GA
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